GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LIM:GILD) » Definitions » Accounts Payable & Accrued Expense

Gilead Sciences (LIM:GILD) Accounts Payable & Accrued Expense : $0 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Gilead Sciences Accounts Payable & Accrued Expense?

Gilead Sciences's quarterly accounts payable & accrued expense declined from Mar. 2024 ($6,083 Mil) to Jun. 2024 ($5,725 Mil) and declined from Jun. 2024 ($5,725 Mil) to Sep. 2024 ($0 Mil).

Gilead Sciences's annual accounts payable & accrued expense declined from Dec. 2021 ($8,668 Mil) to Dec. 2022 ($5,343 Mil) but then increased from Dec. 2022 ($5,343 Mil) to Dec. 2023 ($5,560 Mil).

Gilead Sciences Accounts Payable & Accrued Expense Historical Data

The historical data trend for Gilead Sciences's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Accounts Payable & Accrued Expense Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,524.00 7,189.00 8,668.00 5,343.00 5,560.00

Gilead Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,386.00 5,560.00 6,083.00 5,725.00 -

Gilead Sciences Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Gilead Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LIM:GILD) » Definitions » Accounts Payable & Accrued Expense
Comparable Companies
BMY PFE AMGN BIIB OGN AMRN SCLX MIRA MRK ABBV LLY OCSE:NOVO B JNJ XSWX:ROG LSE:AZN XSWX:NOVN XPAR:SAN LSE:GSK TSE:4519 TSE:4568
Traded in Other Exchanges
GILD:USA GILD:Mexico 1GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD:Chile GILD34:Brazil GILD:Austria GILD:Argentina
Address
333 Lakeside Drive, Foster, CA, USA, 94404
Website
https://www.gilead.com
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).